Protagonist Therapeutics Inc ( (PTGX) ) has released its Q3 earnings. Here is a breakdown of the information Protagonist Therapeutics Inc presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Protagonist Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of peptide-based therapeutics, primarily targeting inflammatory and hematological disorders.
In its third-quarter 2025 financial report, Protagonist Therapeutics highlighted significant progress in its drug development pipeline, including the submission of a New Drug Application (NDA) for icotrokinra for psoriasis treatment and the advancement of its rusfertide program for polycythemia vera.
Key financial metrics revealed a net loss of $39.3 million for the quarter, with research and development expenses increasing due to heightened drug discovery activities. The company reported cash reserves of $678.8 million, expected to sustain operations through 2028. Strategic collaborations with Johnson & Johnson and Takeda Pharmaceuticals continue to bolster Protagonist’s pipeline, with promising results from clinical trials of icotrokinra and rusfertide.
Looking ahead, Protagonist Therapeutics remains focused on advancing its pipeline, with anticipated NDA approval and commercialization of icotrokinra and rusfertide in 2026. The company is also progressing with early-stage trials for new candidates like PN-881 and triple agonists PN-477sc and PN-477o, reflecting a robust development strategy.